3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Parathyroid Neoplasms
1
Interventions
Cisplatin
35
pembrolizumab
29
Radiotherapy
26
Cetuximab
26
Docetaxel
17
Paclitaxel
13
Fluorouracil
13
Cyclophosphamide
12
fludarabine
11
Radiotherapy, Intensity-Modulated
11
Nivolumab
10
Carboplatin
9
atezolizumab
7
Radiation
7
Gemcitabine
7
Erlotinib Hydrochloride
7
Bortezomib
7
fludarabine phosphate
6
Pemetrexed
5
Interleukin-2
5
Radiosurgery
4
Everolimus
4
Drug Therapy
4
Azacitidine
4
olaparib
3
motexafin gadolinium
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Head and Neck Neoplasms
×
Interleukin-12
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled